Alabama Fertility Welcomes the First INVOcell Baby In the State of Alabama
BIRMINGHAM, Ala. and MEDFORD, Mass., Oct. 30, 2018 /PRNewswire/ — Alabama Fertility, a leading infertility practice in Birmingham, Alabama, today announced the birth of the clinic’s first newborn utilizing INVOcell, the in-vivo fertilization technology from INVO Bioscience (OTC: IVOB). This marks the first baby born from this technique in the state of Alabama.
INVOcell has the ability to transform the way in which doctors assist infertile patients to become pregnant in a simpler, more natural and cost-effective manner. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The simplistic INVOcell procedure can be easily performed in an appropriately trained infertility specialist’s office without the need for expensive overhead.
Beth Malizia, MD, a specialist in infertility and reproductive surgery at Alabama Fertility and the first physician trained in the state of Alabama in the INVOcell technique, said, “We are thrilled to announce the birth of the state of Alabama’sfirst INVOcell baby. Peter was born on September 27, 2018. He is healthy, with no medical complications at the time of birth. He and his mother are thriving. We are blessed to have had a hand in this joyous occasion for this sweet family and we look forward to many others in the years to come. Alabama Fertility is dedicated to providing a broad scope of services and solutions to help those that desire to achieve pregnancy. INVOCell is a unique, and cost effective, alternative that may produce a pregnancy where other treatment options have failed. We are thrilled to welcome Peter to the world and for his lovely family as a result of the INVOcell procedure.”
Katie Karloff, chief executive officer of INVO Bioscience, commented, “This is a joyous occasion for the family, Alabama Fertility and all of us at INVO Bioscience. We are proud that our technology was the enabling force to make this birth possible. Our expectation is that the simplicity, the efficacy and the cost efficiency of the INVOcell process will help many more couples in the years to come to build the families that they so fervently desire.”
About Alabama Fertility
Alabama Fertility is an international referral center for complex reproductive problems including endometriosis, uterine fibroids, congenital abnormalities and infertility. At Alabama Fertility, our experienced doctors are committed to treating each patient as an individual with the understanding and compassion that complex reproductive problems require. We have a caring staff who are dedicated to providing you with a compassionate setting while our office allows for privacy (and free parking!) with a convenient location in Birmingham. We strive to care for you with advanced fertility care in a personalized setting. For more information, please visit www.alabamafertility.com or call (205) 874-0000.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504